Aytu BioPharma, Inc.

Report azionario NasdaqCM:AYTU

Capitalizzazione di mercato: US$24.0m

Aytu BioPharma Gestione

Criteri Gestione verificati 3/4

Aytu BioPharma Il CEO è Josh Disbrow, nominato in Apr2015, e ha un mandato di 11.17 anni. la retribuzione annua totale è $ 883.93K, composta da 66.7% di stipendio e 33.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.93% delle azioni della società, per un valore di $ 464.14K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 9.9 anni.

Informazioni chiave

Josh Disbrow

Amministratore delegato

US$883.9k

Compenso totale

Percentuale dello stipendio del CEO66.75%
Mandato del CEO11.2yrs
Proprietà del CEO1.9%
Durata media del management3.6yrs
Durata media del Consiglio di amministrazione9.9yrs

Aggiornamenti recenti sulla gestione

Articolo di analisi • May 14

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation

Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...
Articolo di analisi • Jun 20

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...

Recent updates

Articolo di analisi • Dec 20

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...
Articolo di analisi • Nov 17

Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...
Articolo di analisi • Oct 30

There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise

Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...
Articolo di analisi • Jul 29

Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...
Articolo di analisi • May 14

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation

Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...
Articolo di analisi • May 04

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
Articolo di analisi • Jan 18

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Articolo di analisi • Nov 15

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...
Articolo di analisi • Nov 01

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Jun 20

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...
Articolo di analisi • Jun 14

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Feb 17

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...
Articolo di analisi • Feb 16

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...
Articolo di analisi • Jan 23

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Articolo di analisi • Sep 29

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...
Seeking Alpha • Oct 13

Aytu stock falls amid suspending clinical programs to save costs

Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.
Seeking Alpha • Sep 27

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.
Seeking Alpha • Sep 14

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.
Seeking Alpha • Aug 16

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16
Seeking Alpha • Aug 09

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.
Articolo di analisi • May 19

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...
Articolo di analisi • Sep 11

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Josh Disbrow rispetto agli utili di Aytu BioPharma?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$34m

Dec 31 2025n/an/a

-US$25m

Sep 30 2025n/an/a

-US$13m

Jun 30 2025US$884kUS$590k

-US$14m

Mar 31 2025n/an/a

-US$1m

Dec 31 2024n/an/a

-US$4m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024US$928kUS$590k

-US$13m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023n/an/a

-US$17m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$8m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Compensazione vs Mercato: La retribuzione totale di Josh ($USD 883.93K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.55K ).

Compensazione vs guadagni: La retribuzione di Josh è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Josh Disbrow (51 yo)

11.2yrs
Mandato
US$883,928
Compensazione

Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Joshua Disbrow
CEO & Director11.2yrsUS$883.93k1.93%
$ 464.1k
Ryan Selhorn
CFO, Corporate Secretary & Treasurer1.6yrsUS$538.65k0.46%
$ 111.4k
Jarrett Disbrow
Chief Business Officer3.6yrsUS$549.25k0.57%
$ 137.9k
Greg Pyszczymuka
Chief Commercial Officer4.4yrsUS$522.08k0.34%
$ 80.9k
Margaret Cabano
Vice President of Operationsno dataNessun datoNessun dato
Gerwin Westfield
Senior Vice President of Scientific Affairs1yrNessun datoNessun dato
3.6yrs
Durata media
49yo
Età media

Gestione esperta: Il team dirigenziale di AYTU è considerato esperto (durata media dell'incarico 3.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Joshua Disbrow
CEO & Director10.4yrsUS$883.93k1.93%
$ 464.1k
Vivian Liu
Independent Director3.9yrsUS$87.76k0.18%
$ 44.4k
John Donofrio
Independent Chairman9.9yrsUS$117.76k0.13%
$ 30.8k
Carl Dockery
Independent Director10.2yrsUS$82.76k0.20%
$ 47.4k
Abhinav Jain
Independent Director3yrsUS$77.76k0.18%
$ 43.7k
9.9yrs
Durata media
59yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AYTU sono considerati esperti (durata media dell'incarico 9.9 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/11 00:54
Prezzo dell'azione a fine giornata2026/06/11 00:00
Utili2026/03/31
Utili annuali2025/06/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Aytu BioPharma, Inc. è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Edward WooAscendiant Capital Markets LLC
Jeffrey CohenLadenburg Thalmann & Company
Thomas FlatenLake Street Capital Markets, LLC